Stock Research for GERN

GERN

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

GERN Stock Chart & Research Data

The GERN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the GERN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


GERN Due diligence Resources & Stock Charts

The GERN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View GERN Detailed Price Forecast - CNN Money CNN View GERN Detailed Summary - Google Finance
Yahoo View GERN Detailed Summary - Yahoo! Finance Zacks View GERN Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View GERN Trends & Analysis - Trade-Ideas Barrons View GERN Major Holders - Barrons
NASDAQ View GERN Call Transcripts - NASDAQ Seeking View GERN Breaking News & Analysis - Seeking Alpha
Spotlight View GERN Annual Report - CompanySpotlight.com OTC Report View GERN OTC Short Report - OTCShortReport.com
TradeKing View GERN Fundamentals - TradeKing Charts View GERN SEC Filings - Bar Chart
WSJ View Historical Prices for GERN - The WSJ Morningstar View Performance/Total Return for GERN - Morningstar
MarketWatch View the Analyst Estimates for GERN - MarketWatch CNBC View the Earnings History for GERN - CNBC
StockMarketWatch View the GERN Earnings - StockMarketWatch MacroAxis View GERN Buy or Sell Recommendations - MacroAxis
Bullish View the GERN Bullish Patterns - American Bulls Short Pains View GERN Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View GERN Stock Mentions - StockTwits PennyStocks View GERN Stock Mentions - PennyStockTweets
Twitter View GERN Stock Mentions - Twitter Invest Hub View GERN Investment Forum News - Investor Hub
Yahoo View GERN Stock Mentions - Yahoo! Message Board Seeking Alpha View GERN Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for GERN - SECform4.com Insider Cow View Insider Transactions for GERN - Insider Cow
CNBC View GERN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for GERN - OTC Markets
Yahoo View Insider Transactions for GERN - Yahoo! Finance NASDAQ View Institutional Holdings for GERN - NASDAQ


Stock Charts

FinViz View GERN Stock Insight & Charts - FinViz.com StockCharts View GERN Investment Charts - StockCharts.com
BarChart View GERN Stock Overview & Charts - BarChart Trading View View GERN User Generated Charts - Trading View




Latest Financial News for GERN


Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
Posted on Thursday March 21, 2024

Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates.


Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Posted on Tuesday March 19, 2024

FOSTER CITY, Calif., March 19, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an underwritten offering consisting of 41,999,998 shares of its common stock at a price of $3.00 per share and pre-funded warrants to purchase 8,002,668 shares of its common stock. The pre-funded warrants are being sold at a price of $2.999 per pre-funded warrant. All of the securities in the offering are to be sold by Geron. The offering included


Geron, Madrigal Pharmaceuticals jump on good news from FDA
Posted on Friday March 15, 2024

Shares of both Geron (GERN) and Madrigal Pharmaceuticals (MDGL) are soaring after receiving positive news from the Food and Drug Administration. For Geron, an FDA advisory panel backed its blood disorder treatment. For Madrigal, the FDA approved its treatment for a liver disease known as nonalcoholic steatohepatitis, or NASH. Yahoo Finance's Josh Lipton and Julie Hyman discuss the stocks' reaction in the video above. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Stephanie Mikulich.


Stocks to Watch Friday: Adobe, Ulta, Fisker
Posted on Friday March 15, 2024

[**Adobe (ADBE)**](https://www.wsj.com/market-data/quotes/ADBE): The software company's latest results topped forecasts, but guidance for its current quarter [disappointed investors](https://www.wsj.com/livecoverage/stock-market-today-dow-jones-03-15-2024/card/adobe-reports-solid-earnings-but-stock-sinks-after-outlook-underwhelms-investors-fg7wmoXAIxD5cpqyO7v8).


Stock Market & Investing Books

Enter a stock symbol to view the stock details.